Evidence map›Paper›PMID 42377985›Full record

ArticleJournal of extracellular vesicles2026

Eliminating PD-L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune-Mediated Tumour Rejection in Mice.

Loes Teeuwen, Loïc Steiner, Chantal Reinhardt, Annemarijn Offens, Jesse E Kuipers, Daniel Martínez-Martínez, Jules Mazouin, Benedict J Chambers, Gözde Güçlüler Akpinar, Susanne Gabrielsson

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Loes TeeuwenDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Loïc SteinerDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6640-3513
Chantal ReinhardtDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-6108-0839
Annemarijn OffensDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Jesse E KuipersDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Daniel Martínez-MartínezDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Jules MazouinDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Benedict J ChambersDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
Gözde Güçlüler AkpinarDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Susanne GabrielssonDivision of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1771-1346

Funding

Karolinska Institutet FoundationsKarolinska Institutet's KID grantThe Cancer Research Foundations of Radiumhemmet 231181The Cancer Research Foundations of Radiumhemmet 251212The Swedish Cancer Society 22-2102 PjThe Swedish Cancer Society 25-4495 PjThe Swedish Medical Research Council 2025-02722The Swedish Medical Research Council VR 2022-01170
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are emerging as promising vehicles for cancer immunotherapy, yet the molecular determinants of their immunogenicity remain poorly defined. While PD-L1 expression on cancer-derived EVs has been shown to suppress immune responses, its role on immunotherapeutic EVs remains unexplored. In this study, we investigated how eliminating PD-L1 from antigen-loaded bone marrow-derived dendritic cell (BMDC) EVs affects the efficacy of EV-based cancer vaccines. We generated and characterized ovalbumin (OVA)-loaded BMDC EVs from wild-type (WT) and PD-L1

Indexed as

B7-H1 AntigenDendritic CellsExtracellular VesiclesImmunotherapyMelanoma, ExperimentalAnimalsCancer VaccinesFemaleMiceMice, Inbred C57BLB7-H1 AntigenCancer VaccinesCd274 protein, mouse

Identifiers

PMID42377985
PMCPMC13317667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.